Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by abnormal
proliferation, lack of cellular differentiation, and infiltration of bone marrow, peripheral blood …

During the last four decades, much progress has been made in understanding the molecular
pathogenesis of acute myeloid leukemia and in identifying prognostic factors predictive of …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Acute myeloid leukaemia (AML) is a malignant disorder of the myeloid blood lineage
characterized by impaired differentiation and increased proliferation of hematopoietic …

Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by impaired
differentiation and uncontrollable proliferation of myeloid progenitor cells. Due to high …

We are witnessing an unprecedented paradigm shift in the treatment of acute myeloid
leukemia (AML). For nearly 4 decades—since the introduction of cytarabine-and …

Acute myeloid leukemia (AML) is the most frequently diagnosed acute leukemia, and its
incidence increases with age. Although the etiology of AML remains unknown, exposure to …

Although the treatment modalities for acute myeloid leukemia (AML) have not changed
much over the past 40 years, distinct progress has been made in deciphering the basic …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …